| Theme | The consideration of polypharmacy in dialysis patients | |
|---|---|---|
| Title | Prescription of antiplatelet and anticoagulant drugs | |
| Publish Date | 2017/04 | |
| Author | Hideki Fujii | Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine |
| [ Summary ] | It is well known that the major cause of death in hemodialysis patients is cardiovascular disease (CVD). Most of these patients have CVD, such as cerebrovascular disease, coronary artery disease, heart failure, peripheral vascular disease, and atrial fibrillation ; therefore, various kinds of antiplatelet and anticoagulation drugs are commonly prescribed for these patients. In the clinical setting, patients taking many such drugs are encountered, and it must be determined whether these drugs are appropriately prescribed based on the patients' cardiovascular lesions. Since heparin is administered for hemodialysis patients at every dialysis session, these patients are at a high risk of bleeding events. Therefore, it is very important to recognize the features and how to manage CVD using antiplatelet and anticoagulation drugs in hemodialysis patients. |
|